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Abstract 
Cryptococcosis is a symptomatic fungal infection caused by Cryptococcus, which frequently 
occurs in patients who are immunologically compromised or chronically ill. Localized in-
volvement of the hepatobiliary system in an immunocompetent adult is extremely rare. We 
report a unique case of isolated biliary cryptococcosis manifesting as obstructive jaundice and 
mimicking hilar cholangiocarcinoma in an immunocompetent woman. By integrating surgical 
and antifungal drug therapy, the disease was effectively controlled. Despite an increasing in-
cidence of biliary malignancies, hepatobiliary surgeons and gastroenterologists must maintain 
a high index of suspicion for other rare possibilities of non-specific biliary inflammation. 
Key  words:  Biliary  cryptococcosis;  Obstructive  jaundice;  Cholangiocarcinoma;  Cryptococcus 
neoformans; Itraconazole. 
INTRODUCTION 
Cryptococcosis is a symptomatic fungal infection 
with worldwide distribution caused by Cryptococcus, 
which frequently occurs in patients who are immu-
nologically  compromised  or  chronically  ill  [1,  2]. 
Clinical  manifestations  are  usually  confined  to  the 
central  nervous  system,  lung  and  skin,  whereas  lo-
calized  involvement  of  the  hepatobiliary  system  is 
rare. We herein present an uncommon case of biliary 
cryptococcosis  mimicking  cholangiocarcinoma  in  an 
immunocompetent woman presenting with obstruc-
tive jaundice. With no evidence of the involvement of 
other organs, we established a diagnosis of isolated 
biliary cryptococcosis. 
CASE REPORT 
A  44-year-old  native  woman  was  admitted  to 
our hospital for right upper quadrant discomfort and 
jaundice in July 2006. The patient had been healthy 
until  4  months  prior  to  admission  when  upper  ab-
dominal pain of unknown origin first began; at that 
time, icteric eyes and skin with darkened urine were 
noted. She felt somewhat nauseous but did not vomit. 
There  was  no  fever,  cough,  headache,  diarrhea  or 
other mental or physical complaints. Despite taking 
ursodeoxycholic acid capsules prescribed by her pri-
mary care provider for 20 days, she still felt malaise 
with no improvement in her symptoms. Three days 
prior to this hospitalization, she experienced a sudden 
onset of colicky pain in the stomach and back. The 
patient’s past medical history and family history were 
unremarkable, and she had not been exposed to any 
drugs, toxins, or blood products. She had been a rural 
resident  until  marriage  as  an  adult  and  resided  in 
town.  She  had  been  in  a  monogamous  relationship 
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with her husband for more than 20 years and had no 
risk factors for HIV infection.  
On  physical  examination,  she  was  a 
well-developed woman with a body weight of 54 kg 
(body mass index: 20.6 kg/m2), although she had lost 
10 kg over the last 4 months. Her vital signs were sta-
ble and within normal limits, and no positive physical 
exam findings except scleral icterus were present. Her 
complete  blood  count,  coagulation  factors,  erythro-
cyte  sedimentation  rate,  serum  immunoglobulin, 
CEA,  AFP  and  CA125  were  normal,  whereas  an-
ti-hepatitis viruses (A-E), anti-HIV and abnormal au-
toimmune antibodies were negative. Urine and stool 
tests were consistent with obstructive  jaundice. The 
liver  function  tests  and  CA19-9  results  are  summa-
rized in Table 1. Moreover, the flow cytometry lym-
phocyte  subpopulations  were  normal  at  49%  CD3+, 
21% CD4+, 23.4% CD8+, and 19.5% natural killer cells 
(TBNKTM,  Latonia,  KY).  Her  chest  CT,  gastroscopy 
and  colonoscopy  demonstrated  no  abnormalities, 
although abdominal ultrasonography revealed extra- 
and  intrahepatic  biliary  dilatation.  The  outer  CBD 
diameter was dilated to 16.1 mm as its maximum, but 
the  lumen  was  narrowed  to  almost  zero  due  to  an 
irregular thickened wall (7.4 mm at its maximum). No 
findings that were consistent with bile duct calculus, 
liver neoplasm or cirrhosis were identified. Further-
more, an abdominal contrast-enhanced CT scan and 
an MRCP produced similar findings, i.e., a hilar bili-
ary stricture with no evidence of abdominal masses or 
lymphadenopathy (Fig. 1). Accordingly, an ERCP was 
performed,  which  revealed  an  isolated  irregular 
proximal CBD stricture with dilated intrahepatic bili-
ary  trees  and  no  duodenal  or  ampullary  tumors  as 
well  as  negative  brush  cytology  (Fig.  2A).  After  a 
multidisciplinary  consultation  with  the  gastroenter-
ologists,  radiologists  and  oncologists,  a  consensus 
diagnosis  of  primary  sclerosing  cholangitis  rather 
than cholangiocarcinoma was made, partly due to the 
lack of malignant features consistent with cholangio-
carcinoma in all of the medical images. Thus, the pa-
tient  was  transferred  to  the  Gastroenterology  Dept. 
and received a conventional diagnostic plan of glu-
cocorticoid–free treatment. Unfortunately, within the 
first  week  posterior  to  the  ERCP,  her  hyperbiliru-
binemia worsened, with TBil and DBil increasing to 
203.5 μmol/L and 123.1 μmol/L, respectively. At that 
time, a repeat MRCP revealed a more indistinct biliary 
bifurcation and CHD, which was pathognomonic for 
malignancy (Fig. 1F). Therefore, a hepatic hilar chol-
angiocarcinoma (Klatskin tumor) emerged as the new 
presumptive diagnosis, and thus, an exploratory lap-
arotomy was scheduled after comprehensive consent 
was obtained. 
Intraoperatively, the liver was noted to be tough, 
green-brown  in  color,  of  generally  normal  size  and 
without  any  masses  or  perihepatic  enlarged  lymph 
nodes.  Thickened  walls  of  the  cystic  duct,  CHD, 
proximal CBD and initial part of the bilateral hepatic 
ducts  were  detected  and  ranged  from  0.5-1.0  cm, 
which consequently narrowed the bile channels. Up-
on  choledochotomy,  packed  gelatin-like  exudates 
were  found  inside  the  lumen,  and  thus,  a  flexible 
choledochoscopy was performed, the results of which 
supported the above findings. The gallbladder and a 
strip of the morbid CBD were removed and submitted 
for  frozen  section  pathological  examination.  Both 
samples  demonstrated  inflammatory  granulomas 
with round refractive corpuscles based on hematoxy-
lin-eosin staining. Therefore, the diagnosis of biliary 
cryptococcosis was made, and only T-tube drainage 
was performed. 
 
Table 1: Summary of the blood tests. 
  1st Admis-
sion 
Pre-ERCP  Post-ERCP  POD1  POD11  2 weeks after 1st 
Discharge 






WBC (/μl)  4,900  5,100  3,000  9,200  5,200  5,300  4,200  4,000  3,800 
Hb (g/L)  116  110  101  103  95  97  112  121  125 
ALT (IU/L)  149  112  100  201  39  21  24  81  25 
AST (IU/L)  209  131  150  278  46  31  42  90  36 
GGT (IU/L)  231  232  295  301  115  69  44  119  58 
ALP (IU/L)  269  284  361  444  210  136  109  206  94 
ALB (g/L)  34.5  30.1  28.8  23.1  31.2  27.3  38.7  38.9  39.5 
TBil (μmol/L)  99.1  160.7  203.5  215.5  123.1  75.2  18.8  83.6  22.6 
DBil (μmol/L)  61.5  85.5  123.1  116.3  83.8  54.7  3.4  55.4  9.7 
TBA(μmol/L)  114.2  99.4  116.0  36.7  23.1  16.6  0.6  120.0  4.0 
CA19-9(U/ml)  132.3  -  -  -  -  -  19.2  15.9  - 





Fig. 1: Abdominal CT and MRCP images at 1st admission. A) Thicken cystic neck, cystic duct and CBD (red arrowheads) on plain scan. B) 
CBD contrast enhancement in a pattern of concentric circles. C) Axial T1-W image showing moderate dilatation of intrahepatic biliary 
radicals in both lobes of the liver with extrahepatic bile ductal thickening. D) Axial T2-W image showing hypointense gross circumferential 
mural thickening of the CBD. E) The first MRCP performed before ERCP showing dilated intrahepatic ducts with abrupt cut-off of their 
lumens in the hilum (green arrowheads). The main pancreatic duct is not observed. F) Second MRCP after ERCP showing more dilated 
intrahepatic ducts with hilar discontinuity. The proximal main pancreatic duct is also observed, whereas the distal duct is not indicated. 
 
Fig. 2: ERCP and postoperative T-tube cholangiography. A) ERCP showing an irregular CBD stricture (red arrowheads) with dilated 





Next,  following  the  operation,  the  blood,  bile, 
sputum, CSF, urine and stool samples were cultured 
simultaneously with ink staining at least in triplicate. 
All samples were  negative for  Cryptococcus, but the 
final paraffin pathology of the intraoperative biliary 
samples  confirmed  the  definite  diagnosis.  Micro-
scopic  examination  demonstrated  numerous  encap-
sulated  yeast-like  organisms  measuring  7-10  μm  in 
diameter scattered in multinucleated giant cells and 
fibrous tissues throughout the CBD and gallbladder 
wall. The periodic acid methenamine silver stain, pe-
riodic acid Schiff stain and India ink  stain  were all 
positive (Fig. 4), whereas the pathogen identified by 
polymerase  chain  reaction  from  the  paraf-
fin-embedded  gallbladder  was  Cryptococcus  neofor-
mans (VNI type
1) [3]. As soon as she completed an 
uneventful recovery, she was transferred to the Gas-
troenterology  Dept.  again  for  anti -fungal  therapy 
(beginning on POD11), an itraconazole regimen con-
sisting of 2 weeks of inpatient intravenous injections 
(Sporanox® IV, Xian-Janssen Pharmaceutical Ltd., Bei-
jing, China) followed by 10 weeks of per os outpatient 
therapy (Sporanox® Capsule). At two weeks after dis-
charge (i.e., 4 weeks after starting the therapy), her 
transaminases had returned to normal levels, whereas 
TBil/DBil  levels  normalized  after  an  additional  4 
weeks.  Moreover,  her  T-tube  was  removed  after  a 
cholangiography (Fig. 2B). 
During  her  follow-ups,  she  appeared  to  have 
some occasional abdominal discomfort, mainly in the 
right upper quadrant, but no jaundice. Regular repeat 
abdominal  ultrasonographies  revealed  no  extra-  or 
intrahepatic  biliary  dilatation,  and  the  thickness  of 
CBD wall dropped to 2.2 mm (April 2009). 
Unexpectedly, more than 4 years after her orig-
inal  presentation  (September  2010),  she  was 
re-hospitalized for hyperbilirubinemia. Similar to the 
first admission, her examination was otherwise nor-
mal, and all body fluids were negative for Cryptococ-
cus. The liver function test results from this presenta-
tion are listed in Table 1. Radiologic exams at this time 
revealed a thickened CBD wall, narrow CBD lumen 
and moderately dilated intrahepatic bile ducts, which 
were also similar to but slightly less severe than her 
initial presentation (Fig. 3). Instead of an ERCP, an 
EUS was performed; it demonstrated a benign change 
of her CBD entirely from the hilar bifurcation to the 
duodenal ampulla. A cholangioenterostomy was un-
der deliberation; however, her icterus gradually and 
                                                       
1 Identified by the Medical Mycology Laboratory, Xinhua 
Hospital, School of Medicine, Shanghai Jiaotong University 
in February 2012. The materials and methods are detailed in 
Ref. [3]. 
spontaneously vanished. By the 14th inpatient day, the 
patient had recovered and was again discharged. As 
of the time of this writing, another 16 months of fol-
low-up have passed with no abnormalities detected. 
DISCUSSION 
Cryptococcus is a yeast that is present in the en-
vironment  worldwide.  Most  species  appear  to  be 
nonpathogenic to humans and animals, with the no-
table exceptions of Cryptococcus neoformans (formerly 
C. neoformans var. neoformans) and Cryptococcus gattii 
(formerly  C.  neoformans  var.  gattii)  [3].  Clinically, 
cryptococcosis is known as an uncommon fungal in-
fection that primarily affects patients with impaired T 
cell-mediated  immunity,  such  as  the  following:  pa-
tients with liver cirrhosis, systemic lupus erythema-
tosus, diabetes mellitus, or hematologic malignancies; 
patients  with  a  history  of  systemic  corticosteroid 
therapy, immunosuppressive treatments, solid organ 
transplantation  or  splenectomy;  and  HIV-positive 
patients [1, 2]. The lung and central nervous system 
are the two most commonly affected sites, followed 
by the skin, prostate, eyes, adrenal glands and me-
dullary  cavity  of  the  bones  [4].  Cryptococcal  in-
volvement of the biliary system within the context of 
disseminated cryptococcosis in HIV-negative patients 
has occasionally been reported [5-11]. However, iso-
lated biliary involvement in an otherwise normal pa-
tient as an initial presentation is exceedingly rare [12, 
13].  
In the present case, our assumption of “isolated 
biliary cryptococcosis” is reasonable, although  there 
was no definitive autopsy evidence as  provided by 
Bucuvalas et al [12]. First, the patient was an appar-
ently  healthy  adult  before  and  after  she  developed 
this illness, who runs her family firm competently and 
lives a happy personal life. During the 6-year period 
of clinical surveillance, no signs of impaired immun-
ity have been identified. Second, neither clinical nor 
radiological infection findings in the central nervous 
system  or  lungs  were  noted.  The  Cryptococ-
cus-negative bile, sputum, blood, CSF and stools ex-
clude  the  possibility  of  disseminated  mycosis.  The 
thorough exploration at the time of laparotomy and 
the  repeat  medical  imaging  confirm  the  sole  in-
volvement of the biliary system. In theory, primary 
biliary cryptococcosis seems to be unlikely; however, 
this does occur in the rare instances in which implan-
tation of the fungus is introduced directly into the bile 
duct  [6].  Secondary  biliary  cryptococcosis  can  be  a 
downstream sequela to liver or disseminated visceral 
cryptococcosis due to cryptococcemia in the system-
atic circulation or portal system, which is termed "the 






Fig. 3: Abdominal CT and MRCP at 2nd admission. A) Arterial phase and B) Venous phase CT scan demonstrating apparently normal 
intrahepatic and extrahepatic bile ducts (red arrowheads denoting CBD). C) Fast-echo MRI hydrography demonstrating slight dilatation of 




Fig. 4: Microscopic examination with India ink staining (400x magnification). Numerous encapsulated yeast-like organisms measuring 7-10 





Simultaneously, intestinal inhabitation of  Cryp-
tococcus may be transmitted by "ascending" infection 
of the biliary tree [12, 14]. In our case, the route of 
infection is quite uncertain, as neither primary lesions, 
lymphadenectasis, nor hepatosplenomegaly are pre-
sent. On the other hand, the human body in its role as 
the  defender  of  infection  can  typically  mount  ade-
quate host defenses to this organism by virtue [15]. 
Thus,  clinically  apparent  cases  of  cryptococcosis  in 
healthy hosts are rare, although unintentional expo-
sure is most likely common. Evidence also indicates 
that cryptococcosis usually manifests as a reactivation 
of  a  dormant  infection  originating  from  significant 
environmental exposure during childhood when re-
peated  inquination  may  be  necessary  to  establish  a 
latent fungal burden that can be reactivated in adult-
hood  [16].  In  summary,  the  etiology  of  our  case  is 
suspected to be a dormant ascending cholangitis due 
in part to the patient’s rural upbringing. Furthermore, 
using  molecular  medicine  techniques,  we  identified 
the exact type of Cryptococcus that was involved in this 
case, C. neoformans (VNI type). Although C. gattii is the 
species that is principally responsible for infections in 
immunocompetent hosts, it is rarely reported in China 
because  it  is  geographically  restricted  to  countries 
with tropical and subtropical climates and the tem-
perate climate of North America [3]. 
From the perspective of preoperative diagnosis, 
it is relatively difficult to reach a precise decision. The 
clinical  manifestations  are  almost  not  specific,  pre-
senting an unknown cause of biliary wall thickening 
and obstructive jaundice. Radiologically in this case, 
the thickened CBD exhibits a contrast enhancement in 
a pattern of concentric circles on the CT scans, and 
shows a hypointense gross circumferential mural on 
the axial T2-W MRI images; these may be the charac-
teristic features of biliary cryptococcosis, according to 
past  experiences  from  the  systemic  cryptococcosis 
with hepatobiliary involvement [8-13]. However, an 
important difference between this case and the dis-
seminated cryptococcosis is the absence of lymphad-
enectasis,  which  just  verifies  the  circumscription 
within  the  biliary  system.  The  main  differential  di-
agnoses are listed in Table 2. In terms of treatments, a 
surgical intervention was necessary for this patient, as 
it was impractical to obtain reliable pathological data 
on  bile  ducts  except  during  surgery.  Analogously, 
biliary obstructive lesions should be treated as chol-
angiocarcinomas, whenever a malignancy is not defi-
nitely excluded [17]. 
The choice of antifungal agents depends on the 
site of infection and the immune status of the patient. 
These agents include the amphotericin B, azoles (e.g., 
fluconazole,  itraconazole),  and  flucytosine.  Antifun-
gal therapy should be initiated as early as possible, as 
delays  in  antifungal  therapy  are  associated  with 
poorer clinical outcomes including increased mortal-
ity [18]. The recommended initial standard treatment 
for cryptococcal meningitis in HIV-infected adults is 
the  amphotericin  B  combined  with  flucytosine  ad-
ministered  over  at  least  a  2-week  induction  period 
followed by fluconazole for 8 weeks. Itraconazole is 
considered an acceptable but less effective alternative. 
Given the hyperbilirubinemia in our patient, we se-
lected itraconazole over amphotericin B because of the 
latter’s slighter higher hepatotoxicity, and this choice 
proved to be satisfactory. 
In summary, we present a unique case of isolated 
biliary  cryptococcosis  in  an  immunocompetent 
woman.  Despite  an  increasing  incidence  of  biliary 
malignancies,  hepatobiliary  surgeons  and  gastroen-
terologists must have a high degree of suspicion for 
other rare causes of non-specific biliary inflammation, 
thus avoid unnecessary operations for such cases. 
 
Table 2: The differential diagnosis of conditions causing thickened biliary walls and jaundice. 
Benign bile duct tumors  Benign cholangiopathy  Infectious diseases  Malignancy 
papilloma  primary sclerosing cholangitis  bacterial cholangitis  lymphoma 
adenoma  eosinophilic cholangiopathy   biliary tract stone disease  carcinoma 
fibroma  follicular cholangitis  hepatobiliary tuberculosis   
neurinoma  iatrogenic bile duct stricture  parasitic cholangitis   
leiomyoma  ischemic cholangiopathy  clonorchiasis sinensis   
hamartoma    ascariasis   
granular cell myoblastoma    schistosomiasis   
adenomyoma    fluke   
carcinoid       
 






AFP, alpha fetoprotein; ALP, alkaline phospha-
tase;  ALT,  alanine  aminotransferase;  AST,  aspartate 
aminotransferase; CA125 (19-9), carbohydrate antigen 
125 (19-9); CBD, common bile duct; CEA, carcinoem-
bryonic  antigen;  CHD,  common  hepatic  duct;  CSF, 
cerebrospinal fluid; CT, computed tomography; DBil, 
direct serum bilirubin; ERCP, endoscopic retrograde 
cholangiopancreatography;  EUS,  endoscopic  ultra-
sonography;  GGT,  γ-glutamyltransferase;  HIV,  hu-
man immunodeficiency  virus; MRCP,  magnetic res-
onance  cholangiopancreatography;  MRI,  magnetic 
resonance imaging; POD, postoperative day(s); TBA, 
total bile acid; TBil, total serum bilirubin. 
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